In non-small cell lung cancer (NSCLC), acquired Nrf2 hotspot mutations demonstrate functional synergy with secondary anaplastic lymphoma kinase (ALK) mutations, conferring therapeutic resistance to second-generation ALK inhibitors [98]. This evidence concerns the gene ALK and non-small cell lung carcinoma.